文献速递肝病

MASH症状患者报告结局量表的开发与验证:CLDQ-MASH症状问卷

Development and Validation of a Symptom-Based Patient-Reported Outcome Measure for MASH: The CLDQ-MASH Symptom Questionnaire.
PubMed 文献 · Am J Gastroenterol · 2026-07-31

本研究基于全球MASLD注册登记数据,开发并验证了针对MASH的症状特异性患者报告结局量表。开发样本n=2,066,验证样本n=2,541,最终形成36条目、8个症状领域的CLDQ-MASH症状问卷,各领域评分可区分组织学疾病严重程度及肝硬度分级,心理测量学属性良好。

要点

  • CLDQ-MASH症状问卷为36条目、8领域,是首个针对MASH验证的症状特异性量表
  • 8个领域中7个Cronbach α>0.80,内部一致性高
  • 领域评分可区分早期纤维化、F2-F3与肝硬化,以及肝硬度<10、10-20、>20 kPa

核心结论

  • CLDQ-MASH症状问卷是首个针对MASH验证的疾病特异性症状量表,心理测量学属性良好。

研究设计与样本

  • 基于全球MASLD注册登记中具有临床数据且完成CLDQ-MASH问卷的MASLD受试者。
  • 开发样本n=2,066,用于量表开发与初步验证;验证样本n=2,541,为独立验证样本。
  • 开发阶段从CLDQ-MASH条目及其他通用量表的症状相关条目经专家输入识别50条症状条目,去除冗余后保留36条进行探索性因子分析。
  • 验证采用患者报告结局量表的标准流程。

主要发现

  • 36条目分布于8个症状领域:精神、认知、疲劳、全身、腹部、健康困扰、睡眠障碍和外周症状。
  • 8个领域中7个Cronbach α>0.80,显示高内部一致性;外周症状领域包含多样条目。
  • 在开发样本和独立验证样本中,各领域评分均可显著区分组织学疾病严重程度(早期纤维化 vs F2-F3 vs 肝硬化)。
  • 各领域评分可显著区分肝硬度分级(<10 vs 10-20 vs >20 kPa)。
  • 量表可基于非肝脏合并症(2型糖尿病、高血压、精神疾病、睡眠、瘙痒、临床明显疲劳、GERD、其他胃肠疾病)进行良好区分。

关键数值与推荐

  • 36条目、8领域;7/8领域Cronbach α>0.80。
  • 开发样本n=2,066,验证样本n=2,541。
  • 肝硬度分组阈值:<10、10-20、>20 kPa。
  • 组织学严重程度分组:早期纤维化、F2-F3、肝硬化。

临床怎么用

  • 可作为标准化工具用于临床研究及常规实践,全面评估MASH疾病负担和治疗反应。
  • 需进一步外部验证后方可推广作为标准化工具。

局限性

  • 研究基于全球MASLD注册登记数据,需进一步外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Metabolic dysfunction-associated steatohepatitis (MASH) is associated with a substantial symptom burden. However, no validated symptom-focused patient-reported outcome instrument exists for this population. We aimed to develop and validate the MASH Symptom Questionnaire. METHODS: We analyzed subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) from the global MASLD registry with clinical data and completed Chronic Liver Disease Questionnaire-MASH (CLDQ-MASH) instruments. For the new instrument development and preliminary validation, we used CLDQ-MASH items supplemented with symptom-related items from other generic instruments (development sample: n = 2,066) and expert input. A list of 50 symptom-related items was identified. After removal of redundancy, 36 items were retained and evaluated using exploratory factor analysis. Standard pipeline for validation of a patient-reported outcome instrument was applied. The instrument was validated using another independent validation sample from global MASLD registry (validation sample: n = 2,541). RESULTS: In the development phase, 36 items were distributed in 8 symptom domains: mental, cognitive, fatigue, systemic, abdominal, health distress, sleep disturbance, and peripheral symptoms domains. Seven of 8 domains demonstrated a Cronbach alpha >0.80 (high internal consistency); the remaining peripheral symptoms domain included diverse items. The domain scores significantly discriminated across histologic disease severity (early fibrosis vs. F2-F3 vs. cirrhosis), liver stiffness categories (<10 vs. 10-20 vs. >20 kPa) in both development and independent validation samples. The instrument discriminated well based on nonhepatic comorbidities (type 2 diabetes, hypertension, psychiatric, sleep, pruritus, clinically overt fatigue, GERD, other GI disorders). Similar strong validation properties were noted in the independent validation sample. DISCUSSION: The 36-item, 8-domain CLDQ-MASH Symptom Questionnaire represents the first validated, disease-specific symptom questionnaire for patients with MASH showing good psychometric properties. With further external validation, the CLDQ-MASH Symptom Questionnaire has the potential to serve as a standardized tool in both clinical research and routine practice to comprehensively assess disease burden and treatment response.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Stepanova M, Younossi I, et al. Development and Validation of a Symptom-Based Patient-Reported Outcome Measure for MASH: The CLDQ-MASH Symptom Questionnaire. Am J Gastroenterol. 2026. PMID: 42536024. doi:10.14309/ajg.0000000000004171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。